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Abstract
The idiopathic Tn-syndrome, formerly called ‘permanent mixed-field polyagglutinability’, is a rare hematological disorder
characterized by the expression of the Tn-antigen on all blood cell lineages. The immunodominant epitope of the Tn-antigen
is terminal K-N-acetylgalactosamine, O-glycosidically linked to protein. Normally this residue is 3P-substituted by L-galactose
thereby forming the core 1 structure known as the Thomsen^Friedenreich (TF) antigen (GalL1D3GalNAcK1DThr/Ser).
The cause of the exposure of the Tn-antigen appears to be due to the silencing of the gene expression of
L1,3galactosyltransferase, since treatment of deficient Tn(+) lymphocyte T clones with 5Pazacytidine or Na butyrate leads
to reexpression of enzyme activity and the sialylated TF-antigen. The Tn-syndrome is acquired and permanent and affects
both sexes at any age. Its origin is unknown. Pluripotent stem cells are affected since all lineages are involved but each one to
a variable extent. Therefore, normal cells co-exist with Tn-transformed cells. Clinically, patients suffering from the
Tn-syndrome appear healthy. Laboratory findings usually reveal moderate thrombocyto- and leukopenia and some signs of
hemolytic anemia not warranting any treatment. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The idiopathic Tn-syndrome occupies a unique po-
sition in the ¢eld of glycosylation disorders for two
reasons: First, it is up till now the only known per-
manent, well de¢ned disorder of O-glycosylation and
second, the disorder is acquired and con¢ned to a
fraction only of hemopoietic cells of all lineages.
The disorder is due to a complete absence of UDP-
Gal:N-acetylgalactosaminideL1,3galactosyltransfer-
ase activity (EC 2.4.1.122; 1,3GT) in the a¡ected
cells. Therefore, the Tn-antigen is exposed on blood
cells. In addition to the idiopathic Tn-syndrome, Tn-
antigens may also occur on cell surfaces in a variety
of malignant disorders as a cancer-associated epiphe-
nomenon. These aspects are not included in this re-
view.
Several reviews on the Tn-syndrome have been
published [1,2].
2. Pathways of O-glycosylation
Recent work has unravelled an astonishing diver-
sity of O-glycosidic structures. The best known are
the ubiquitous GalNAc core and its common sub-
stituents as shown in Fig. 1. Additional O-glycosidic
glycans built on O-mannosyl- [3] or O-fucosyl-pep-
tide [4] cores have recently been identi¢ed which are
not relevant in the present context. Normally, pep-
tide-linked O-KGalNAc is substituted by Gal in a
L1C3 linkage catalyzed by 1,3GT to form the so-
called core 1 structure (for review see [5]). Unsubsti-
tuted peptide-linked KGalNAc has antigenic proper-
ties and is designated as the Tn-antigen (Fig. 1). Un-
substituted GalL1C3GalNAcK-R (core 1) is called
the TF-antigen (formerly called T-antigen) according
to Thomsen^Friedenreich.1 Usually the core 1 struc-
ture is bisialylated as shown in Fig. 1. Removal of
sialic acids unmasks the TF-antigen which, therefore,
is called a cryptantigen. In some cases the Tn-antigen
can be substituted by sialic acid in a K2C6 linkage
to GalNAc thus forming the sialosyl-Tn-antigen.
Other possible pathways are shown in Fig. 1. Note
that core 2 formation does not occur in the absence
of 1,3GT because of the absolute requirement of the
GlcNAc-T branching L1C6 N-acetylglucosaminyl-
transferase for the core 1 substrate (for review see
[5]).
3. Discovery and early work
The Tn-syndrome was originally described by
Moreau and Dausset et al. [6,7] in 1957, based on
the observation that certain red cells can be aggluti-
nated by all human sera irrespective of their ABH
blood group status. This phenomenon was usually
ascribed to ‘aging’ of erythrocytes in sera obtained
from patients with infections and was most probably
due to a microbial neuraminidase activity which un-
masked the TF-antigen. By contrast, these authors
described a patient who exhibited the phenomenon
of polyagglutinability for many years and who also
had leukopenia, thrombocytopenia and a chronic he-
molytic anemia. Careful serologic di¡erentiation per-
mitted to establish an antigen di¡erent from the TF-
antigen: This antigen was then called Tn. This re-
markable ¢rst description of a case with Tn-syn-
drome already contained the suggestion of an ac-
quired immune hemolytic disease triggered by a
microbial, probably viral infection which unmasks
or modi¢es a latent antigen. The chemical nature
of this antigen was unknown at that time.
4. Clinical ¢ndings
The prevalence of the Tn-syndrome is extremely
1 The formerly used designation of T-antigen for the Thom-
sen^Friedenreich antigen should be abandoned because of possi-
ble confusion with retroviral T-antigens.
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low; it is impossible to give a reliable ¢gure but its
occurrence among normal blood donors must be be-
low 1 in 150 000 as we did not ¢nd a single case by
screening this high a number [1]. Besides the classical
case described by Moreau and Dausset [6,7], a few
other clinical reports are available. They are sum-
marized in Table 1. In summary, patients a¡ected
by the idiopathic Tn-syndrome generally do well ex-
cept for minor signs of hemolysis or thrombocytope-
nia. They are usually found by alert technicians test-
ing blood in normal blood donors or in patients for
an unrelated clinical problem and observing the phe-
nomenon of polyagglutinability. If referred to an ex-
pert in blood group serology, these cases may be
further investigated. Often, a thorough work-up is
not deemed important since therapeutic consequen-
ces are not warranted. Hence, many cases may es-
cape undiagnosed. However, the patient reported by
Haynes et al. [12] had a bleeding disorder as a con-
sequence of thrombocytopenia. Interestingly, in this
case survival of heterologous erythrocytes was found
normal leading the authors to suggest a stem cell
disorder since the exogenous red blood cells did
not acquire the property of polyagglutinability dur-
ing more than four months. In Tn(+) patients, the
Coombs tests usually are negative despite the
fact that anti-Tn Igs are ubiquitously present in se-
rum.
Importantly, recent work carried out in many lab-
oratories has con¢rmed and extended work pio-
neered by Springer in identifying the Tn-antigen as
a cancer-associated antigen, together with the TF-
and the sialosyl-Tn-antigens [23]. It is beyond the
scope of this review to critically assess and summa-
rize this work. Su⁄ce to note that unmasking of the
Tn-antigen in cancer may induce a T-cell associated
Fig. 1. Biosynthetic pathways of O-glycans and structures of TF-, Tn- and sialosyl-Tn-antigens. The main membrane component har-
bouring O-glycans on erythrocytes is glycophorin, on leukocytes leukosialin (or CD43). Further modi¢cations of the core 1 structures
are described in [5].
BBADIS 61874 13-9-99
E.G. Berger / Biochimica et Biophysica Acta 1455 (1999) 255^268 257
Table 1
Tn-syndrome: clinical ¢ndings
Patient Sex Age
(years)
Duration
of Tn-
trans-
formation
(years)
Eca
(U106/Wl)
Retb
(%)
Lcc
U103/Wl
Thcd
U105/Wl
Hbe
(% or
g/100 ml)
Htf
(%)
Clinical
symptoms
Obser-
vations
Ref.
MT m 65 9 2.7 ^ 2.87 1.12 60 30 Anemia requiring
transfusions
Improvement upon
treatment with
prednisone
[6,7]
A m 63 4 months 3 4.2 ^ ^ 61 ^ The patient su¡ered
from bronchial
carcinoma unrelated
to the Tn condition
Acquired condition
since all family
members tested were
negative
[8]
Vr m 88 ^ ^ 7.5 ^ ^ 8.9 ^ Signs of hemolytic
anemia
[8]
B.A. f 18 10 months ^ 2 2 0.55, 0.70 13.8 ^ Healthy Persistence of Tn
transformation
2.5 years later con¢rmed
involvement of platelets
demonstrated
[9^11]
N.N.1g m 53 8 noh no 2.4 0.18 ^ ^ No evidence for
hemolysis, but
bleeding disorder
Survival of heterologous
erythrocytes in this
patient was normal;
splenectomy had no
in£uence on
thrombocytopenia
[12]
O.S. m 28 s 4 1.3 ^i ^ 13.3 ^ ^ Healthy 50% of erythrocytes
direct Coombs test
negative
[13]
R.M. m 56 s 3 no no no no no ^ Healthy ‘Mosaic status’ [14]
R.K. f 36 1 ^ ^ 2.8 0.64 13.1 ^ None Bone marrow normal [15]
R.R. m 18 ^ ^ ^ ^ ^ ^ Healthy unrelated
clinical problems due
to accident
Mosaic status, 93% of
erythrocytes Tn(3)
transformed
[16,28]
D.J.H. ^ 20 ^ ^ ^ Lowered Lowered ^ ^ Urinary bleeding,
stomatitis, chronic
gingivitis
95% of erythrocytes
Tn-transformed
[17]
C.C. ^ 24 ^ no ^ no 4^5 ^ ^ Asymptomatic
moderate
thrombocytopenia
100% of erythrocytes
Tn-transformed
[17]
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Table 1 (continued)
Tn-syndrome: clinical ¢ndings
Patient Sex Age
(years)
Duration
of Tn-
trans-
formation
(years)
Eca
(U106/Wl)
Retb
(%)
Lcc
U103/Wl
Thcd
U105/Wl
Hbe
(% or
g/100 ml)
Htf
(%)
Clinical
symptoms
Obser-
vations
Ref.
Az ^ ^ ^ ^ ^ ^ 0.70 ^ ^ ^ Tn(+) transformed
platelets identi¢ed
[11]
Du ^ ^ ^ ^ ^ ^ 0.53 ^ ^ ^ Separation of normal
from Tn-transformed
platelets which lacked
1,3GalT activity
[11]
P.L. m 27 ca. 1 no Slightly
elevated
2.9 0.45 no no ^ Low haptoglobin bone
marrow normal
[18]
M.Z. f 61 Several
years
4.5 ^ 3.5 1.56 13.7 39.8 ^ [19]
R.P.T f 35 0.5 ^ ^ ^ ^ ^ ^ ^ [20]
Rob f 22 no no no no no no ^ [21]
N.N.2g m 55 3.91 1.9 1.4 0.18 Bleeding disorder Coombs test negative [22]
aEc, erythrocytes.
bRet, reticulocytes.
cLc, leucocytes.
dThc, platelets.
eHb, Hemoglobin, 100% de¢ned as 14.5 g/100 ml.
f Ht, Hematocrit.
gN.N., not named.
hno, normal.
iNot determined or not reported.
B
B
A
D
IS
61874
13-9-99
E
.G
.
B
erger/B
iochim
ica
et
B
iophysica
A
cta
1455
(1999)
255^268
259
immune response, a ¢nding currently exploited in
immunotherapy trials [24].
5. Structure of the Tn-antigen
As early as in 1973, Sturgeon et al. [16] suggested
on the basis of reduced electrophoretic mobility of
Tn(+) erythrocytes and their reduced content of
sialic acid that ‘a biosynthetic defect common to all
of these aberrations could be a block in the transfer
of terminal D-galactose to N-acetylgalactosamine in a
substantial proportion of heterosaccharide chains of
red cell membrane glycoproteins’. Since the common
O-linked bisialylated core 1 structure was already
known to occur on glycophorin [25], it was a
straightforward task to reveal the Tn-antigen as ter-
minal KGalNAc by chemical analysis. This has been
achieved by Dahr et al. [26] using L-elimination of
the O-glycans followed by gas chromatography:
Whereas glycans isolated from normal controls
were identi¢ed as GalL1C3GalNAc-ol, free N-ace-
tylgalactosaminitol was found in material derived
from two di¡erent Tn(+) patients (Ba, Am). Togeth-
er with serological data, Dahr concluded that the Tn-
antigen consists of terminal K-GalNAc. Subsequent
work by Hesford et al. [27] con¢rmed the presence of
terminal KGalNAc residues on glycoproteins derived
from Tn(+) erythrocytes of the case RR: Tn(+) er-
ythrocyte membranes could be used as acceptor sub-
Table 2
Reagents used to detect the Tn-antigen: monoclonal antibodies
Designation Antigen Biochemical characterization Iso-type Observations Ref.
5F4 (mouse) Asialo-OSM KGalNAc and underlying
structures, nca
IgM Binds Tn(+) T lymphocytes T [30]
CU-1 (mouse) Glycoprotein released by Lu65
human lung squamous carcinoma
cells
Tn-antigen derived from
immunogen, glycophorin A
and asialo-OSM
IgG3 Not crossreactive with A
antigen
[31]
6E6-H5-G9
(mouse)
Tn(+) erythrocytes nc IgM Crossreacts with asialo-OSM [32]
T9 2c (rat) TF(+) erythrocytes; desialylation
of normal erythrocytes uncovers
small amounts of Tn-antigen
nc IgM [32]
12H5-C9-G11 Tn(+) erythrocytes nc IgM Crossreacts with asialo-
OSM
[32]
NCC-LU-81 Membrane fraction derived from
human lung carcinoma Lu65 cells
KGalNAc-O-peptide IgM Crossreacts with A antigen [32,33]
B72.3 Membrane fraction derived from
human mammary carcinoma cells
nc IgG1 Rel. low a⁄nity to
asialo-OSM recognizes also
sialosyl-Tn
[29,34]
83D4 (mouse) Human breast carcinoma cells Mucin-like Tn-determinant
containing membrane protein
present in MCF-7 breast
carcinoma cells
[35]
Etn 1.01 Tn(+) erythrocytes nc IgM [36]
MLS128 (mouse) Human colonic cancer cells
LS180
Glycopeptides derived from
LS 180 cells, OSM or
asialo-OSM
IgG3 Not crossreactive with A
antigen; GalNAc recognized
even if 2C6 substituted by
NeuAc
[37]
164H.1 Synthetic Tn-conjugates:
KGalNAc-human serum albumin
All seven cases of colon
carcinomas stained positive
on frozen sections
[38]
Puri¢ed human
anti-A antibodies
Do not react with Tn Blood group A epitope IgM [15]
anc, not characterized.
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strates for the newly identi¢ed erythrocyte membrane
1,3GT [28]: Normal donor erythrocyte membranes
solubilized in Triton X-100 did not incorporate la-
beled galactose from UDP-[14C]Gal, neither did
Tn(+) erythrocyte membranes incorporate label.
However, mixing normal with Tn(+) membrane ly-
sates led to signi¢cant incorporation of label into
glycophorin as shown by autoradiography of electro-
phoretically separated erythrocyte membranes. Tn(+)
cell derived glycophorins have been investigated by
Jokinen [13] and by Blumenfeld et al. [17]. Jokinen
found substantial amounts of terminal O-linked Gal-
NAc, but also, surprisingly, di- and tetrasaccharides.
Since the Tn(+) pool of erythrocytes had to be sep-
arated by free-£ow electrophoresis from the Tn(3)
subset, some contamination may explain the occur-
rence of di- and tetrasaccharides in glycophorins of
the Tn(+) subset. Alternatively, residual 1,3GT in
Tn(+) cells might have given rise to these products.
Blumenfeld et al. [17] analyzed the carbohydrate
composition of isolated glycophorins without prior
separation of Tn(+) from Tn(3) subsets and found
less Gal and NeuAc in Tn(+) than in control glyco-
phorins, while N-glycans seemed to be present. Inter-
estingly, L-eliminated glycans contained a disaccha-
ride composed of equal amounts of NeuAc and
GalNAcol which, upon digestion with Clostridium
perfringens neuraminidase, was cleaved whereas no
cleavage was seen with Newcastle disease virus neur-
aminidase which preferentially cleaves K2C3 link-
ages. Thus, the authors concluded that substantial
amounts of the sialosyl-Tn structure were present
and, in fact, con¢rmed a previous report by Kjeldsen
et al. [29] of the occurrence of sialosyl-Tn on Tn-
erythrocytes: these authors determined the presence
of sialosyl-Tn using a panel of monoclonal antibod-
ies to the Tn or the sialosyl-Tn epitope, respectively.
The development of mAbs and the use of more
speci¢c lectins are of considerable help in identifying
the Tn-antigen (Tables 2 and 3).
6. All blood cells are involved
Early clinical work already led to the suggestion
that Tn-transformation a¡ects stem cells at an early
stage of di¡erentiation [12] since thrombocytopenia
and leukopenia have frequently been observed (cf.
Table 1). Involvement of platelets [11] and granulo-
cytes [18] has been demonstrated by Cartron, Vain-
chenker and associates. A striking reduction of the
sugar content of platelet membrane glycoproteins
GP1b and glycocalicin was noted. In the Tn-patients,
Cartron and Nurden [11] also found a dual popula-
tion of platelets (normal and Tn(+), respectively)
with a ‘mosaic status’ analogous to that already
Fig. 3. Immuno£uorescent detection of the Tn-antigen on eryth-
rocytes (A) and burst forming units-erythroid colonies (B) using
FITC-labeled HPA. As shown on panel B, all cells are positive
indicating expression of Tn as a clonal feature. Reproduced
from Vainchenker et al. [18] by copyright permission from Am.
Soc. Clin. Invest.
Fig. 2. Immuno£uorescence of erythrocytes of patient R.R.
Neuraminidase-treated erythrocytes were stained using a mAb
to the TF-antigen as described [43]; examples are indicated
with arrowheads. 7% of all red blood cells exhibit the TF-anti-
gen, thus appear normal. 93% have been shown to be Tn(+),
thus not reactive with the mAb [16,28].
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found for erythrocytes (see Fig. 2). The biochemical
phenotype of Tn-platelet membrane glycoproteins
was also compared with those derived from a patient
with Bernard^Soulier syndrome and a patient with
thrombasthenia, respectively; in both these condi-
tions 1,3GT activity was normal [11]. The glycopro-
tein GP1b of a patient with Tn-syndrome (Patient
B.A., Table 1) was more thoroughly investigated by
2-dimensional gel electrophoresis and lectin binding
studies and shown to be the major membrane com-
ponent exposing the Tn-antigen [44].
In a series of elegant studies the clonal expression
of the Tn-antigen was then demonstrated in eryth-
roid (as expected) and granulocyte colonies [18,44]:
Fig. 4. Flow cytometric analysis of ex vivo T cell clones from patient R.R. VCN designates treatment with Vibrio cholerae neuramini-
dase prior to analysis. Analysis has been carried out using mAb TKH6 to the Tn-antigen (panels, A,B,E,F) or mAb 22.19 to the TF-
antigen (panels C,D,G,H). Reproduced from Thurnher et al. [43] by copyright permission from Eur. J. Immunol.
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peripheral blood and bone marrow cells were grown
ex vivo from patients P.L. and B.A. (Table 1) under
conditions to expand clonally as burst-forming units-
erythroid and colony-forming units-granulocyte-mac-
rophage. These cells were then stained using HPA-
FITC and shown to uniformly express the Tn-anti-
gen or to lack it thereby demonstrating clonality of
Tn-expression (cf. Fig. 3). These data also con¢rmed
the presence of two types of stem cells explaining the
dual expression pattern of normal and Tn-trans-
formed cells. As a spin-o¡ of this study the authors
also showed clonality of expression of the Tn-antigen
in the megakaryocyte colony assay. Subsequent stud-
ies carried out by £ow cytometry con¢rmed these
data [44]. Since all these lineages are involved, a so-
matic mutation at the pluripotent stem cell level must
be assumed. In this respect this condition recalls par-
oxysmal nocturnal hemoglobinuria (for review see
[45,46]). More recently, erythroid cells from a donor
with Tn-syndrome (patient N.N., see Table 1, [22])
were expanded in vitro and co-cultured with cells
from a normal donor. In this in vitro system of
mixed cultures the normal cells proved to have a
growth advantage over those expressing the Tn-anti-
gen. By contrast, in a culture of patient cells only,
which initially had only 1.4% of Tn(+) cells, the
Tn(+) subset expanded to 62.9% on day 9. This re-
Fig. 5. L1,3 Galactosyltransferase activity in 6 di¡erent Tn(+)
and 3 TF(+) T cell clones. 1,3GT activity is given as nmol/min
per mg of protein and was measured using asialo-OSM as sub-
strate [28]. Reproduced from Thurnher et al. [43] by copyright
permission from Eur. J. Immunol.
Table 3
Reagents used to detect the Tn-antigen: lectins
Type Epitope recognized Crossreactive Inhibitable by
(concentrations indicate
50% inhibition)
Observation Ref.
Dolichos bi£orus KGalNAcs LGalNAc A1 200 nmol/200 Wl
K-methylGalNAc
[40]
Moluccella laevis KGalNAc A, N GalNAc Binds to Tn
lymphocytes
[30]
May weakly
bind to Gal
Asialo-OSM, asialo-
agalacto-glycophorin
[41]
As above, sialosyl-
Tn
Agglutination of Tn
erythrocytes
[39]
Vicia villosa isolectin
B4
KGalNAc Co-crystallization
of B4 lectin with
GalNAc
[42]
Salvia sclarea KGalNAc Tn-speci¢c, not
crossreactive
with A
[39,40]
Helix pomatia KGalNAcs
KGlcNAcs
LGalNAcs
LGlcNAcs
KGal
A 2.2 nmol/200 Wl K-
methylGalNAc; 1.9 nmol/200 Wl
methyl N-bromoacetyl KGal
[40]
Lima bean KGalNAcs LGalNAc [40]
Soy bean agglutinin K,LGalNAcsK,LGal 2.5 nmol/200 Wl GalNAc;
2.5 nmol/200 Wl methyl
LGalNAc; 2 nmol/200 Wl methyl
N-bromoacetyl KGalNAc
[40]
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sult recalls somewhat Thurnher’s data [47] showing
overgrowth of Tn(+) lymphocytes in a culture previ-
ously treated with 5Pazacytidine and reexpressing the
TF-antigen.
The same group also provided evidence for the
involvement of B and T cells in the Tn-syndrome
[48] at a time when CD markers were not yet avail-
able. Therefore, quantitation was done by micro-
scopic counting of HPA-labeled cells double stained
with antibodies to Ig chains. While the percentage of
Tn-transformed B-cells was around 50%, that of T
cells was quite low, around 1 to 2%, a ¢nding later
con¢rmed by £ow cytometry in case R.R. [43]. The
possibility to immortalize B cells by Epstein^Barr
virus infection was applied to the investigation of
Tn-transformation by Gahmberg et al. [49]: EBV-
transformed cells derived from a patient with
blood-type 0 were stained with the HPA lectin and
cloned by FACS. The resulting clones were uni-
formly lacking or expressing the Tn-antigen for
over 1 year. The membrane proteins were analyzed
and a 105 kDa glycoprotein was shown to react
strongly with galactose oxidase prior to neuramini-
dase treatment of Tn(+) cells and to bind HPA, sug-
gesting the presence of terminal KGalNAc. For rea-
sons not understood, further cultivation of these B
lymphoblastoid cells seemed di⁄cult [50], a ¢nding
con¢rmed by Thurnher et al. (unpublished). Avail-
ability of mAbs to the TF and the Tn-antigen ren-
dered isolation and cloning of Tn(+) T lymphocytes
possible: Thurnher et al. generated a number of T
cell clones from patient R.R. (Fig. 4) and showed
absence of 1,3GalT activity in lysates of Tn(+) cell
clones [43] (Fig. 5). Moreover, he showed that
CD3(+), CD4(+) and CD8(+) subsets occurred
among both Tn(+) and Tn(3) populations. Using
Limax £avus lectin £ow cytometry, the amount of
sialic acid on Tn(+) T cells was estimated to be re-
duced by 50%. Thus, these cells can be considered as
constitutively hyposialylated and were used as mod-
els to study binding of various lectins including
Amaranthus caudatus, Maackia amurensis, Sambucus
Fig. 6. Reexpression of TF-antigen and CD43NeuAc. Reactivation in Tn(+) cells by treatment with 5Pazacytidine. Tn(+) lymphocytes T
derived from patient R.R. were treated with 5Pazacytidine and analyzed by £ow cytometry for the expression of the Tn-antigen (upper
panels), TF-antigen (middle panels) and CD43NeuAc using the mAbs TKH6, HH8 and DF-T1, respectively, with and without prior
treatment with neuraminidase. The arrows indicate 5Pazacytidine-induced changes. Upper row: appearance of Tn(3) subset; middle
row: appearance of a TF(+) subset (binds antibody after neuraminidase only); lower row: appearance of CD43 (using a mAb speci¢c
for sialylated epitopes). Reproduced from Thurnher et al. [47] by copyright permission from Am. Soc. Clin. Invest.
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nigra and Triticum vulgare lectins, respectively [51]:
binding characteristics were compatible with defec-
tive O- but intact N-glycosylation. Moreover, these
cells were also investigated for their binding of hu-
man siglecs (for de¢nition see [52]) such as siaload-
hesin (Sn), myelin-associated glycoprotein (MAG)
and CD22. MAG and Sn binding, respectively were
shown to be reduced to 19% and 33%, respectively,
of control cells.
7. Molecular basis of the Tn-syndrome
Little is yet known about the causes leading to Tn
transformation. A block in the transfer of Gal has
been postulated by Sturgeon et al. based on serolog-
ical observations [16]. Indeed, using asialo-OSM or
p-nitrophenyl GalNAc as acceptor substrates, Berger
and Kozdrowski, [28] and Cartron et al. [53], respec-
tively, con¢rmed this prediction using detergent-solu-
bilized membranes of a¡ected erythrocytes. Impor-
tantly, both groups were able to detect the enzyme
activity in serum [53,54]. Thus, absence of 1,3GalT
seems to be con¢ned to blood cells. Further analysis
of this enzyme de¢ciency is hampered by lack of
antibodies and genetic information. The enzyme
has been remarkably resistant to all attempts at pu-
ri¢cation to homogeneity as well as cloning but has
been characterized quite thoroughly on the basis of
activity measurements (for review see [2]).
The main question to be answered in any case of
enzyme de¢ciency is its origin: is it the consequence
of a structural mutation or of silencing of gene ex-
pression?
This question can only be answered with some
con¢dence once the sequence of the corresponding
cDNA and the gene will have been elucidated. A
tentative answer has been given by Thurnher et al.
[47], who treated Tn(+) lymphocytes T with 5Pazacy-
tidine or butyrate, respectively: treated cells reex-
pressed the TF-antigen along with sialylated CD43
both as a result of reactivated and measurable
1,3GalT in lysates of these cells (Fig. 6). Re-express-
ing cells were kept in culture for several weeks and
shown to revert to the original phenotype for reasons
not understood. Recently qualitative similar results,
i.e., some re-expression of the TF-antigen following
treatment of lymphocytes T by the agents mentioned
above were obtained in another patient (Patient
M.Z.) [19]. Strikingly, the proportion of Tn(+) eryth-
rocytes in the peripheral blood is, in most cases, over
50% and, in some cases, nearly 100%. By contrast,
Tn(+) lymphocytes in the circulating blood do not
exceed a few percent. The reason for this discrepancy
is unknown. Two possibilities may be discussed: ei-
ther Tn(+) transformation is associated with some
proliferative advantage in the case of erythroid line-
ages and/or disadvantage in the case of lymphoid
cells. Alternatively, expression of the Tn-antigen
may be associated with the behaviour of blood cells
in circulation, leading to sequestration of Tn(+) lym-
phoid cells in lymphatic organs.
8. Outlook
Recent developments in molecular biology of gly-
cosyltransferases have revealed an unexpected diver-
sity of these enzymes since probably all of them exist
as families comprising ¢ve to over ten related molec-
ular species. Sensu stricto these are isoenzymes since
they are encoded by di¡erent, often syntenic genes.
Examples include the family of K1,3fucosyltransfer-
ases (for review, see [55]), K2,3sialyltransferases (for
review, see [56]), L1,4galactosyltransferases [57] and
the recently cloned L1,3galactosyltransferases [58].
While some of the recombinant enzymes within this
family of L1,3GalTs incorporate to a low extent
LGal into terminal KGalNAc, convincing demonstra-
tion of a high catalytic activity has not been
achieved. Therefore, 1,3GT may be unrelated to
any of the known structures of this family and per-
haps even belong to another family of core 1 struc-
ture forming galactosyltransferases. Circumstantial
evidence for this possibility is the ubiquity of the
core 1 structure and the fact that in the Tn-syndrome
only blood cells are a¡ected. In the case of the ex-
istence of a family of 1,3GTs, all members except one
are completely inactive in blood cells since in Tn-
transformed cells, no residual activity could be meas-
ured. In any case, after treatment of Tn-transformed
cells with 5Pazacytidine or Na butyrate, re-expression
of activity may not necessarily re£ect reappearance
of the silenced isoenzyme. In fact, the reactivated
1,3GT could be due to one or more members of
the putative gene family. However, the ¢ndings of
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Jokinen [13] suggest the possibility of residual activ-
ity in a¡ected cells, compatible with a leaky muta-
tion. In this case the underlying cause of the enzyme
de¢ciency can as well be a mutation in the protein-
coding part leading to loss of function. Obviously,
these questions to be answered need unequivocal
cloning and expression of the 1,3GT operating in
blood cells.
If the assumption of an acquired silencing of
1,3GT proves correct, elucidation of the mechanisms
on how an expression of a de¢ned glycosyltransfer-
ase is down-regulated may be of considerable interest
to understand developmental regulation of glycosyl-
transferase genes.
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